Bridging the Lab and the Ledger: Francis Kamero on Driving R&D Excellence
Research and development in the home and personal care sector is increasingly becoming a strategic driver of business growth across the Middle East and Africa. Success requires not only scientific innovation but also operational precision, regulatory compliance, and consumer-centric solutions that deliver consistent performance across diverse markets.
Francis Kamero has spent his career bridging the gap between laboratory research and industrial execution, transforming ideas into commercially successful products while embedding sustainability and compliance at every stage. Drawing on his experience leading multi-category portfolios and high-investment launches, he has developed a unique approach to R&D that balances creativity, discipline, and measurable business impact.
Home & Personal Care Middle East & Africa conducted an interview with Francis Kamero about his career journey, his strategies for fostering innovation and collaboration within R&D teams, and how he ensures products are technically robust, consumer-relevant, and commercially viable across the region.
HPCMEA: Could you share an overview of your career journey and the experiences that shaped your approach to R&D, innovation, and leadership?
FRANCIS: I began my R&D journey with a background in applied chemistry, learning early in Quality Assurance and Production Management that innovation succeeds when it scales efficiently and performs consistently. Transitioning from the laboratory to plant operations exposed me to shop-floor realities, underscoring the need for robust R&D to anticipate manufacturing and supply chain constraints. Leading multi-category portfolios and high-investment flagship launches taught me to balance creativity with disciplined execution, prioritize impactful innovations, and refine existing offerings. Today, I focus on building structured systems and processes that turn ideas into reliable, commercially successful, consumer-focused solutions across the Middle East and Africa.
HPCMEA: How has your professional background shaped your approach to problem-solving, decision-making, and leadership in R&D?
My experience has shaped me into a consumer-centric problem solver who evaluates product development through Scientific Validity, Operational Feasibility, and Commercial Viability. I define clear objectives at the start of every project and use well-defined guardrails to ensure innovation aligns with consumer needs, purpose, and price. Effective leadership in R&D, which I call “guided autonomy,” combines structured frameworks like the 7-Gate innovation pipeline with freedom for researchers to experiment confidently. By embedding purpose, structure, and accountability and encouraging cross-functional exposure, I ensure R&D delivers commercially viable solutions while building trust and connecting teams to tangible business outcomes.
HPCMEA: What strategies do you use to foster curiosity, experimentation, and collaboration among your researchers, and how have you guided talent to achieve breakthroughs?
I use a “delegative stewardship” approach, giving researchers ownership within clear technical guardrails to create a structured, purposeful environment where curiosity drives results. Every experiment is treated as an opportunity to explore product efficacy, cost, and consumer benefit, while early cross-functional collaboration with procurement, production, and marketing grounds objectives in real business realities. I recently coached two junior scientists through a complex stability challenge, guiding them from following instructions to investigating underlying rheological drivers, which led to a critical stability fix for a major relaunch. This approach not only delivered tangible results but also developed their confidence and capabilities, transforming them into articulate technical leads who manage their own portfolios and make decisions that ensure sustainable business resilience.
HPCMEA: How do you balance scientific excellence, consumer trends, and business objectives when developing new products, and can you share a development challenge and how your team overcame it?
Balancing technical depth with commercial timelines requires clarity from the start, using strategic vision boards, business cases, and feasibility assessments to align innovation with market objectives. Scientific innovation must address real consumer needs, identifying friction points and trade-offs to engineer solutions that are technically robust, commercially relevant, and sustainable. For example, a personal care range for a highly price-sensitive market prioritized sensorial appeal, consistency, and fragrance longevity, resulting in rapid adoption and meaningful revenue growth. When a flagship product required reformulation to meet updated regulatory standards, we identified key performance drivers, collaborated with suppliers to develop alternative materials, and leveraged accelerated stability testing to deliver a compliant, cost-efficient formulation without compromising efficacy.
HPCMEA: What are the key steps in turning a concept from the lab into a product that performs well across different markets in the Middle East and Africa?
FRANCIS: Success across the Middle East and Africa requires bridging laboratory excellence with industrial execution, aligning global technical standards to regional realities. We start with contextual benchmarking, testing formulations under local conditions like heat, humidity, and water hardness to ensure efficacy. Scalability, pilot validation, and regulatory compliance, including KEBS, ESMA, and SFDA, protect formula integrity, supply stability, and adherence to regional frameworks. Controlled adaptation ensures products maintain standardized performance while allowing packaging, pricing, and positioning to remain commercially credible across diverse markets.
HPCMEA: You delivered 10+ new SKUs across foods and non-foods with 100% first-time regulatory approval. What metrics or practices contributed to this success?
FRANCIS: I believe compliance must start at the concept stage, not at submission, which is why we embed the ‘Compliance by Design’ model into R&D. Gate Zero integration involves Regulatory and QA from ideation, identifying high-risk ingredients and claims early to prevent costly reformulations. Progressive documentation and First-Time Right (FTR) standards ensure dossiers are complete and internally validated throughout development. Proactive regulatory mapping across the Middle East and Africa anticipates evolving standards, making approvals predictable and reducing commercial risk.
HPCMEA: How do you navigate evolving regulations while encouraging innovation, and how do regulatory requirements impact project timelines in MEA markets?
FRANCIS: I view regulation as a structural part of innovation, providing clarity that allows scientists to work confidently within defined boundaries. During the implementation of GHS under KS 2606 in Kenya, my team proactively audited raw materials, identified high-hazard substances, and reformulated with safer alternatives, turning a potential disruption into a competitive advantage. Regulatory requirements across MEA markets directly affect launch sequencing and working capital, with reactive development often causing 3–6 month delays or late-stage reformulations. By mapping compliance from the prototype stage and progressively compiling technical dossiers, we make launch schedules predictable, reduce risk, and enable disciplined resource allocation.
HPCMEA: What systems or processes help maintain consistency, safety, and quality from prototype to mass production?
FRANCIS: Consistency is a promise to the consumer, upheld through predictable operational precision and bridging lab development with full-scale manufacturing via pilot validation and strict FTR scorecards. Quality is engineered into every stage through real-world simulation, testing prototypes under mechanical, thermal, and regional storage stresses to ensure lab results scale accurately. Structured gate reviews and strict change control safeguard performance, safety, and compliance during scale-up. Integrated knowledge transfer ensures production teams fully adopt lab intent, with progressive technical files and training guaranteeing reliable outcomes in every batch.
HPCMEA: How do you integrate sustainability into R&D, from ingredients to packaging, without compromising performance, and which emerging trends will shape the next 3–5 years?
FRANCIS: I treat sustainability as a core R&D input, embedding biodegradable and naturally derived ingredients that match conventional performance while supporting supply resilience. We prioritize cold-processable systems, concentrated formulations, and higher active content to reduce energy use, manufacturing costs, and supply-chain impact, while preserving efficiency and affordability. Over the next 3–5 years, sustainability will be engineered first at the formula level, then expressed through packaging and compliance, requiring integrated solutions across ingredients, processing, and packaging. Applied circularity, lighter mono-material packaging, and regulatory enforcement as a legal standard will make safer chemistry, concentration, and streamlined packaging essential to deliver both environmental and commercial value.
HPCMEA: How do you work with suppliers or cross-functional teams to ensure sustainable practices are implemented throughout the product lifecycle?
FRANCIS: Sustainability only scales when embedded across the full value chain, not just within R&D. Structured supplier integration and cross-functional alignment ensure raw materials meet biodegradability, hazard, traceability, and supply resilience criteria, while procurement, manufacturing, and regulatory teams validate cost, efficiency, and compliance. When managed this way, sustainable practices become standard operations, strengthening margins and long-term competitiveness.
HPCMEA: How do you balance sustainability objectives with product affordability?
FRANCIS: Sustainability and affordability are balanced by optimizing core operations, ensuring products remain relevant to target consumers. We focus on formulation design, process efficiency, packaging, waste control, and supplier stewardship to reduce material intensity, energy use, and resin consumption. Close collaboration with raw material manufacturers secures safer, stable inputs while mitigating price volatility through long-term partnerships. Capturing efficiencies across these areas delivers products that are sustainable, commercially competitive, and affordable.
HPCMEA: What skills and strategies do you prioritize when developing, motivating, and retaining top R&D talent?
FRANCIS: When developing and retaining top R&D talent, I prioritize technical expertise, commercial awareness, and structured problem-solving skills. I look for researchers who are curious, data-driven, and understand how their formulation decisions impact supply chains and consumer value. I focus on retention by providing growth, exposure, and ownership, including opportunities to collaborate across functions like procurement, marketing, and suppliers. When my scientists can see how their technical work directly influences revenue, cost, and regulatory success, they stay motivated, engaged, and empowered to deliver measurable business impact.
HPCMEA: How do you create a culture that fosters learning, experimentation, and innovation among your researchers, and can you share an example of a team-led innovation that demonstrates the impact of this approach?
FRANCIS – I’ve found that structured autonomy combined with high accountability drives the best growth. By setting clear technical guardrails through gated frameworks and standardized processes, I give my researchers the space to experiment and prototype rapidly, treating failure as valuable, documented, hypothesis-driven data. A great example is when my team led a shift from hot- to cold-processing for a high-volume liquid detergent. By optimising surfactants, they not only created a stable product but also reduced the factory’s energy consumption and shortened batch cycles by 25%, a success they owned from concept to production, showing how disciplined freedom can deliver meaningful operational and environmental impact.
HPCMEA: Which emerging ingredients, technologies, or consumer trends do you believe will define the next wave of innovation in the sector?
FRANCIS: Innovation is shifting toward multifunctional ingredients that deliver multiple benefits in a single system, enabling minimalistic formulations that maximize consumer value. Bio-synthetic alternatives are becoming essential, offering high performance with improved environmental profiles to meet sustainability goals without compromising efficacy. AI-led digital integration allows predictive modelling of stability, compatibility, and performance, compressing development timelines and moving R&D from reactive trial-and-error to proactive “predict and produce” frameworks. Ultimately, the rise of informed consumers demanding transparency and responsible chemistry drives organisations to balance performance, responsibility, and speed to thrive in the future.
HPCMEA: How do you see R&D evolving over the next 5–10 years in home and personal care?
FRANCIS: Over the next decade, R&D will evolve from a siloed laboratory function into a core driver of business strategy. Organisations will integrate R&D at the earliest stages of commercial planning, aligning technical roadmaps with business objectives. This requires leaders who combine formulation expertise with strategic and cross-functional leadership, positioning technical innovation as the primary engine for sustainable revenue growth and market differentiation.
HPCMEA: What advice would you give to R&D teams or leaders looking to stay ahead and maintain a competitive edge in this industry?
FRANCIS: To remain competitive in volatile markets, R&D leaders must ground every innovation in the consumer’s reality, ensuring products solve tangible problems at a sustainable price. They must bridge technical depth with commercial judgement, understanding margin structures, manufacturability, regulatory exposure, and supply chain constraints to protect both cost and brand equity. Every technical decision should be evaluated not only for performance but for its impact on consumer perception and market success. Finally, leaders must build talent with the same intent as products, giving researchers cross-functional exposure and outcome ownership to develop both technical expertise and business literacy.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.
